Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Howard Hughes Medical Institute
American Cancer Society
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Physiology (medical),Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference42 articles.
1. Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism and disease. Cell 168, 960–976 (2017).
2. Kubrusly, M. S. et al. A role for mammalian target of rapamycin (mTOR) pathway in non-alcoholic steatohepatitis-related cirrhosis. Histol. Histopathol. 25, 1123–1131 (2010).
3. Guillén, C. & Benito, M. mTORC1 overactivation as a key aging factor in the progression to type 2 diabetes mellitus. Front. Endocrinol. 9, 621 (2018).
4. Ardestani, A., Lupse, B., Kido, Y., Leibowitz, G. & Maedler, K. mTORC1 signaling: a double-edged sword in diabetic β cells. Cell Metab. 27, 314–331 (2018).
5. Lee, P. L., Tang, Y., Li, H. & Guertin, D. A. Raptor/mTORC1 loss in adipocytes causes progressive lipodystrophy and fatty liver disease. Mol. Metab. 5, 422–432 (2016).
Cited by
144 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献